The existence of a local 5-hydroxytryptaminergic system in peripheral arteries

British Journal of Pharmacology

Volumn 154, Issue 3, 2008, Pages 663-674

  Ni, W ^a   Geddes, T J ^b   Priestley, J R C ^a   Szasz, T ^a   Kuhn, D M ^b   Watts, S W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

5 Hydroxytryptamine; Monoamine oxidase; Serotonin; Tryptophan hydroxylase; Vascular smooth muscle

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; FENFLURAMINE; NORADRENALIN; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MESENTERIC ARTERY; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROTONIN METABOLISM; SEROTONIN RELEASE; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; BLOTTING, WESTERN; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; ISOMETRIC CONTRACTION; MALE; MESENTERIC ARTERY, SUPERIOR; MONOAMINE OXIDASE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS; TRYPTOPHAN HYDROXYLASE;

EID: 44349132074     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.111     Document Type: Article

References (29)

1. Buzzi MG, Moskowitz MA (2005). The pathophysiology of migraine: year 2005. J Headache Pain 6: 105-111.
2. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H, Koepsell H et al. (2001). Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 21: 6348-6361.
3. Cohen ML, Landry AS, Hemrick SK, Fuller RW (1979). Norepinephrine, monoamine oxidase, and acetylcholinesterase in the rat jugular vein compared with other blood vessels. Can J Physiol Pharmacol 57: 1246-1250.
4. Cooke JP, Marshall JM (2005). Mechanisms of Raynaud's disease. Vasc Med 10: 293-307.
5. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, Pletscher A (1990). 5-Hydroxytryptamine kinetics and activation of blood platelets in patients with essential hypertension. Hypertension 15: 267-273.
6. Gillis CN, Pitt BR (1982). The fate of circulating amines within the pulmonary circulation. Annu Rev Physiol 44: 269-281.
7. Green RA (2006). Neuropharmacology of 5-hydroxytryptamine. Br J Pharmacol 146: 306-312.
8. Griffin M, Casadio R, Bergamini CM (2002). Transglutaminases: nature's biological glues. Biochem J 368 (Part 2): 377-396.
9. Hara K, Hirowatari Y, Yoshika M, Komiyama Y, Tsuka Y, Takahashi H (2004). The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. J Lab Clin Med 144: 31-37.
10. Haycock JW, Kumer SC, Lewis DA, Vrana KE, Stockmeier CA (2002). A monoclonal antibody to tryptophan hydroxylase: applications and identification of the epitope. J Neurosci Methods 114: 205-212.
11. Kuhn DM, Arthur Jr RE (1996). Inactivation of brain tryptophan hydroxylase by nitric oxide. J Neurochem 67: 1072-1077.
12. Kuhn DM, Arthur Jr R, States JC (1997). Phosphorylation and activation of brain tryptophan hydroxylase: identification of serine-58 as a substrate site for protein kinase A. J Neurochem 68: 2220-2223.
13. MacLean MR, Herve P, Eddahibi S, Adnot S (2000). 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131: 161-168.
14. Ni W, Watts SW (2006). 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 33: 575-583.
15. Ni W, Li MW, Thakali K, Fink GD, Watts SW (2004a). The fenfluramine metabolite (+)-norfenfluramine is vasoactive. J Pharmacol Exp Ther 309: 845-852.
16. Ni W, Lookingland K, Watts SW (2006). Arterial 5-hydroxytryptamine transporter function is impaired in deoxycorticosterone acetate and N-omega-nitro-L-arginine but not spontaneously hypertensive rats. Hypertension 48: 134-140.
17. Ni W, Thompson JM, Northcott CA, Lookingland K, Watts SW (2004b). The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 43: 770-781.
18. Pihel K, Hsieh S, Jorgenson JW, Wightman RM (1998). Quantal corelease of histamine and 5-hydroxytryptamine from mast cells and the effects of prior incubation. Biochemistry 37: 1046-1052.
19. Popper CW, Chiueh CC, Kopin IJ (1977). Plasma catecholamine concentrations in unanesthetized rats during sleep, wakefulness, immobilization and after decapitation. J Pharmacol Exp Ther 202: 144-148.
20. Reis F, Tavares P, Fontes Ribeiro CA, Antunes F, Teixeira F (1999). The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. Thromb Res 96: 365-372.
21. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM et al. (1995). Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92: 790-795.
22. Rothman RB, Baumann MH (2002). Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95: 73-88.
23. Small R, Macarak E, Fisher AB (1977). Production of 5-hydroxyindoleacetic acid from serotonin by cultured endothelial cells. J Cell Physiol 90: 225-231.
24. Sugden D (2003). Comparison of circadian expression of tryptophan hydroxylase isoform mRNAs in the rat pineal gland using real-time PCR. J Neurochem 86: 1308-1311.
25. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H et al. (2003a). Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299: 76.
26. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M et al. (2003b). Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115: 851-862.
27. Wang HL (2004). The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension. Curr Opin Investig Drugs 5: 963-966.
28. Watts SW (2005). 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci (London) 108: 399-412.
29. 2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Am J Physiol 276: H944-H952.